Walvax

Maryland-based Sirnaomics announced last week that it will partner with China’s Walvax to co-develop its STP702 RNA interference-based influenza A therapy candidate.
 
Walvax will shell out $6.4 million upfront (plus additional milestone payments) for exclusive development and commercialization rights for STP702 in territories including China, Hong Kong, Macao and Taiwan, the press release said.

Mentions:

The state of the hunt:

The AstraZeneca/Oxford vaccine secured its first authorizations.
  Novavax launched a 30,000-participant North American Phase 3 trial for its recombinant vaccine.
  CNBG claimed 79% efficacy for the inactivated jab from its Beijing subsidiary but provided scant data.

 

Vaccines


Approved or authorized vaccines
 
UK authorizes AstraZeneca/Oxford jab: Britain’s Medicines and Healthcare products Regulatory Agency…

The state of the hunt:

The Pfizer/BioNTech vaccine received several new authorizations, including from the European Union.
  Canada joined the U.S. in authorizing Moderna’s jab. .
  Argentina and Belarus became the first countries outside Russia to OK Sputnik V.

 

Vaccines


Approved or authorized vaccines
 
Pfizer and BioNTech will market their BNT162b2 vaccine in the European Union under the brand name Comirnaty after receiving…

Beijing-based Sinovac announced last week that the China National Medical Products Administration has approved its 23-valent pneumococcal polysaccharide (PPSV23) shot—the company’s first bacterial vaccine licensure, according to the press release.

According to lot release data, Sinovac will compete for PPSV23 market share in China against Beijing Minhai, Chengdu Institute of Biological Products, Merck and Walvax.

In other Chinese vaccine news, Shenzhen Kangtai (BioKangtai)…

The state of the hunt:

Serum Institute of India is reportedly pursuing up to $1 billion in private equity funding for its Covid-19 vaccine projects.
  J&J plans 60,000-participant Phase 3 trials of its Janssen subsidiary’s vaccine candidate.
  Roche will help develop and manufacture Regeneron’s REGN-COV2 antibody cocktail, more than tripling production capacity of the drug.

 

Vaccines

Phase 3 trials:
 
Brazil approved Phase 3 trials of…

The state of the hunt:

Moderna inked a $1.5 billion, 100-million-shot supply deal with the U.S. government for its mRNA vaccine candidate.
  The EU sealed a 400-million-dose vaccine deal with AstraZeneca and agreed to a framework with J&J for up to 400 million more.
  Biological E will produce the investigational vaccine from J&J’s Janssen subsidiary.

 

Vaccines

Clinical trials:

Moderna and Pfizer/BioNTech took steps to modify the…

The state of the hunt:

China sent another inactivated candidate to Phase 2—its fourth vaccine of that type to move beyond Phase 1 trials.
  CEPI has identified manufacturing capacity for 4 billion vaccine doses.
  The WHO-led Access to COVID-19 Tools (ACT) Accelerator is seeking almost $28 billion in additional funds.

 

Vaccines

Clinical trials:

Another Chinese candidate in Phase 2: An inactivated vaccine from the Chinese Academy of Medical…

Manufacturers lined up ahead of Gavi’s donor summit tomorrow to pledge to supply enough human papillomavirus (HPV) shots to reach the vaccine alliance’s updated goal of immunizing at least 84 million girls over the next five years, a Gavi press release said today.

Gavi quoted current suppliers Merck and GSK as saying they would be “dramatically increasing supply” and “continuing to contribute to Gavi’s objective,” respectively.

Meanwhile, Xiamen-based Innovax commented that it…


The state of the hunt: 

AstraZeneca inked a $1 billion deal Thursday with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop and manufacture Oxford University’s recombinant adenovirus vaccine candidate. CanSino’s recombinant shot was found “tolerable and immunogenic” 28 days post-vaccination, according to a preliminary Phase 1 assessment published in The Lancet. Moderna announced positive interim Phase 1 data for its mRNA vaccine.
 

 …


The state of the hunt: 

Novavax became the biggest recipient of CEPI funds for Covid-19 this week, with a new $384 million award for its recombinant protein vaccine candidate. CureVac’s mRNA vaccine candidate induced high levels of virus-neutralizing titers at a low dose in preclinical studies. Gilead announced voluntary royalty-free licenses for remdesivir with five generic drug manufacturers, and more may be in the works.
 

 

Vaccines

Our Covid-19…